192 related articles for article (PubMed ID: 34881693)
1. Nomograms including the controlling nutritional status score in patients with hepatocellular carcinoma undergoing transarterial chemoembolisation for prediction survival: a retrospective analysis.
Chen Y; Xu WJ; Yang Y; Xin YJ; Zhang XY; Li X; Zhou X
Br J Nutr; 2022 Nov; 128(10):1966-1974. PubMed ID: 34881693
[TBL] [Abstract][Full Text] [Related]
2. Controlling nutritional status (CONUT) score-based nomogram to predict overall survival of patients with HBV-associated hepatocellular carcinoma after curative hepatectomy.
Lin ZX; Ruan DY; Jia CC; Wang TT; Cheng JT; Huang HQ; Wu XY
Clin Transl Oncol; 2020 Mar; 22(3):370-380. PubMed ID: 31201606
[TBL] [Abstract][Full Text] [Related]
3. Controlling Nutritional Status (CONUT) Score is Associated with Overall Survival in Patients with Hepatocellular Carcinoma Treated with Conventional Transcatheter Arterial Chemoembolization: A Propensity Score Matched Analysis.
Deng Z; Zhang W; Peng J; Gao L; Zhang C; Lei K; Gong J; Xiong B
Cardiovasc Intervent Radiol; 2024 May; 47(5):592-603. PubMed ID: 38605220
[TBL] [Abstract][Full Text] [Related]
4. Transarterial chemoembolization combined with recombinant human adenovirus type 5 H101 prolongs overall survival of patients with intermediate to advanced hepatocellular carcinoma: a prognostic nomogram study.
He CB; Lao XM; Lin XJ
Chin J Cancer; 2017 Jul; 36(1):59. PubMed ID: 28728568
[TBL] [Abstract][Full Text] [Related]
5. Prognostic significance of controlling nutritional status score-based nomogram for hepatocellular carcinoma within Milan criteria after radiofrequency ablation.
Yang Y; Ye F; Xin Y; Wang Y; Li X; Feng D; Chen Y; Zhou X
J Gastrointest Oncol; 2020 Oct; 11(5):1024-1039. PubMed ID: 33209495
[TBL] [Abstract][Full Text] [Related]
6. Validation of the six-and-twelve criteria among patients with hepatocellular carcinoma and performance score 1 receiving transarterial chemoembolization.
Wang ZX; Li J; Wang EX; Xia DD; Bai W; Wang QH; Yuan J; Li XM; Niu J; Yin ZX; Xia JL; Fan DM; Han GH
World J Gastroenterol; 2020 Apr; 26(15):1805-1819. PubMed ID: 32351295
[TBL] [Abstract][Full Text] [Related]
7. Controlling Nutritional Status (CONUT) Predicts Survival in Gastric Cancer Patients With Immune Checkpoint Inhibitor (PD-1/PD-L1) Outcomes.
Chen L; Sun H; Zhao R; Huang R; Pan H; Zuo Y; Zhang L; Xue Y; Song H; Li X
Front Pharmacol; 2022; 13():836958. PubMed ID: 35308215
[No Abstract] [Full Text] [Related]
8. Immunonutritive Scoring in Patients With Hepatocellular Carcinoma Undergoing Transarterial Chemoembolization: Prognostic Nutritional Index or Controlling Nutritional Status Score?
Müller L; Hahn F; Mähringer-Kunz A; Stoehr F; Gairing SJ; Foerster F; Weinmann A; Galle PR; Mittler J; Pinto Dos Santos D; Pitton MB; Düber C; Kloeckner R
Front Oncol; 2021; 11():696183. PubMed ID: 34178694
[TBL] [Abstract][Full Text] [Related]
9. The prognostic role of controlling nutritional status and skeletal muscle mass in patients with hepatocellular carcinoma after curative treatment.
Tamai Y; Iwasa M; Eguchi A; Shigefuku R; Sugimoto R; Tanaka H; Kobayashi Y; Mizuno S; Nakagawa H
Eur J Gastroenterol Hepatol; 2022 Dec; 34(12):1269-1276. PubMed ID: 36317773
[TBL] [Abstract][Full Text] [Related]
10. The prognostic value of controlling nutritional status (CONUT) score-based nomogram on extranodal natural killer/T cell lymphoma patients.
Zhang S; Sun C; Chen X; Li D; Hu L; Zhang M; Zhang X; Zhang H; Ye J; Wang L; Jia T; Zhu T; Miao Y; Wang C; Wang L; Yan D; Shen Z; Sang W
Ann Hematol; 2023 Jun; 102(6):1433-1442. PubMed ID: 37074377
[TBL] [Abstract][Full Text] [Related]
11. Prognostic nomogram model for selecting between transarterial chemoembolization plus lenvatinib, with and without PD-1 inhibitor in unresectable hepatocellular carcinoma.
Sheng Y; Wang Q; Liu H; Wang Q; Chen W; Xing W
Br J Radiol; 2024 Feb; 97(1155):668-679. PubMed ID: 38303541
[TBL] [Abstract][Full Text] [Related]
12. Controlling nutritional status (CONUT) score-based nomogram to predict overall survival of patients with pancreatic cancer undergoing radical surgery.
Dang C; Wang M; Zhu F; Qin T; Qin R
Asian J Surg; 2022 Jun; 45(6):1237-1245. PubMed ID: 34493426
[TBL] [Abstract][Full Text] [Related]
13. Controlling Nutritional Status (CONUT) score is a prognostic marker in III-IV NSCLC patients receiving first-line chemotherapy.
Zhang Y; Kong FF; Zhu ZQ; Shan HX
BMC Cancer; 2023 Mar; 23(1):225. PubMed ID: 36894927
[TBL] [Abstract][Full Text] [Related]
14. A multi-institutional study to predict the benefits of DEB-TACE and molecular targeted agent sequential therapy in unresectable hepatocellular carcinoma using a radiological-clinical nomogram.
Liu K; Zheng X; Lu D; Tan Y; Hou C; Dai J; Shi W; Jiang B; Yao Y; Lu Y; Cao Q; Chen R; Zhang W; Xie J; Chen L; Jiang M; Zhang Z; Liu L; Liu J; Li J; Lv W; Wu X
Radiol Med; 2024 Jan; 129(1):14-28. PubMed ID: 37863847
[TBL] [Abstract][Full Text] [Related]
15. Nomograms for Predicting Outcomes after Chemoembolization in Patients with Nonmetastatic Hepatocellular Carcinoma.
Ha Y; Han S; Shim JH; Ko GY; Yoon HK; Sung KB; Lee D; Kim KM; Lim YS; Chung YH; Lee YS; Lee HC
J Vasc Interv Radiol; 2015 Aug; 26(8):1093-1101.e1. PubMed ID: 26077020
[TBL] [Abstract][Full Text] [Related]
16. Development of a computed tomography-based radiomics nomogram for prediction of transarterial chemoembolization refractoriness in hepatocellular carcinoma.
Niu XK; He XF
World J Gastroenterol; 2021 Jan; 27(2):189-207. PubMed ID: 33510559
[TBL] [Abstract][Full Text] [Related]
17. Controlling Nutritional Status (CONUT) Score is Associated with Overall Survival in Patients with Unresectable Hepatocellular Carcinoma Treated with Lenvatinib: A Multicenter Cohort Study.
Shimose S; Kawaguchi T; Iwamoto H; Tanaka M; Miyazaki K; Ono M; Niizeki T; Shirono T; Okamura S; Nakano M; Suga H; Yamaguchi T; Yokokura Y; Noguchi K; Koga H; Torimura T
Nutrients; 2020 Apr; 12(4):. PubMed ID: 32295043
[TBL] [Abstract][Full Text] [Related]
18. A novel nomogram based on the nutritional risk screening 2002 score to predict survival in hepatocellular carcinoma treated with transarterial chemoembolization.
Chen X
Nutr Hosp; 2022 Aug; 39(4):835-842. PubMed ID: 35916127
[TBL] [Abstract][Full Text] [Related]
19. Intermediate stage hepatocellular carcinoma: Comparison of the value of inflammation-based scores in predicting progression-free survival of patients receiving transarterial chemoembolization.
Liu Y; Shi M; Chen S; Wan W; Shen L; Shen B; Qi H; Cao F; Wu Y; Huang T; Chen G; Mo J; Ye D; Zhang Y; Feng Z; Fan W
J Cancer Res Ther; 2021 Jul; 17(3):740-748. PubMed ID: 34269308
[TBL] [Abstract][Full Text] [Related]
20. Prognostic nomogram for hepatocellular carcinoma patients after transarterial chemoembolization based on des-γ-carboxy prothrombin reactivity and modified Response Evaluation Criteria in Solid Tumors.
Zhao SM; Qiu LW; Zhao H; Gu WW; Yang XH; Gu ZX; Shi RF; Ni CF
J Cancer Res Ther; 2021 Jul; 17(3):707-714. PubMed ID: 34269303
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
